Suchergebnisse - "Eskazan, Ahmet Emre"

PubPharm (7)

1

Gilteritinib in the management of acute myeloid leukemia : Current evidence and future directions

enthalten in: Leukemia research | 2022

von Nuhoğlu Kantarcı, E. | Eşkazan, A.

2

Novel therapeutic approaches in chronic myeloid leukemia

enthalten in: Leukemia research | 2020

von Özgür Yurttaş, N. | Eşkazan, A.

3

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

enthalten in: Leukemia research | 2018

von Eskazan, A. | Tiribelli, M.

4

Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

enthalten in: Leukemia research | 2014

von Eskazan, A. | Eyice, D. | Kurt, E. | +11

5

Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

enthalten in: Leukemia research | 2014

von Eskazan, A. | Eyice, D. | Kurt, E. | +11

6

Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib : is that true for all the patients?

enthalten in: Leukemia research | 2011

von Eskazan, A. | Soysal, T. | Erbilgin, Y. | +2

CommentOn: Leuk Res. 2010 Apr;34(4):e91-3. - PMID 19811824

7

Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?

enthalten in: Leukemia research | 2011

von Eskazan, A. | Soysal, T. | Erbilgin, Y. | +2

1
[1]